NCT02404415

Brief Summary

The Vanderbilt Atrial Fibrillation Ablation registry (VAFAR) is a prospective clinical and genetic biorepository that systematically enrolls patients undergoing atrial fibrillation (AF) ablation. The registry was started in 2011 and has greater than 1000 AF ablation records with stored blood and DNA samples. The goals of VAFAR are to: 1) identify clinical, genetic, and serological predictors of response to AF ablation in order to improve patient selection, and 2) to provide a resource for translational research investigating the electrophysiologic mechanisms of AF pathogenesis.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,478

participants targeted

Target at P75+ for all trials

Timeline
28mo left

Started Oct 2011

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress86%
Oct 2011Oct 2028

Study Start

First participant enrolled

October 1, 2011

Completed
3.5 years until next milestone

First Submitted

Initial submission to the registry

March 19, 2015

Completed
12 days until next milestone

First Posted

Study publicly available on registry

March 31, 2015

Completed
13.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2028

Last Updated

April 27, 2026

Status Verified

April 1, 2026

Enrollment Period

17 years

First QC Date

March 19, 2015

Last Update Submit

April 21, 2026

Conditions

Atrial Fibrillation

Keywords

catheter ablationgenomics

Outcome Measures

Primary Outcomes (1)

  • Atrial fibrillation recurrence

    2 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Adults scheduled to undergo an atrial fibrillation ablation

You may qualify if:

  • Age \>18 years
  • Able to give written, informed consent
  • Scheduled for an ablation procedure to treat atrial fibrillation

You may not qualify if:

  • \. None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

Location

Related Publications (5)

  • Shoemaker MB, Muhammad R, Farrell M, Parvez B, White BW, Streur M, Stubblefield T, Rytlewski J, Parvathaneni S, Nagarakanti R, Roden DM, Saavedra P, Ellis C, Whalen SP, Darbar D. Relation of morbid obesity and female gender to risk of procedural complications in patients undergoing atrial fibrillation ablation. Am J Cardiol. 2013 Feb 1;111(3):368-73. doi: 10.1016/j.amjcard.2012.10.013. Epub 2012 Nov 17.

    PMID: 23168290RESULT

  • Benjamin Shoemaker M, Muhammad R, Parvez B, White BW, Streur M, Song Y, Stubblefield T, Kucera G, Blair M, Rytlewski J, Parvathaneni S, Nagarakanti R, Saavedra P, Ellis CR, Patrick Whalen S, Roden DM, Darbar R D. Common atrial fibrillation risk alleles at 4q25 predict recurrence after catheter-based atrial fibrillation ablation. Heart Rhythm. 2013 Mar;10(3):394-400. doi: 10.1016/j.hrthm.2012.11.012. Epub 2012 Nov 23.

    PMID: 23178686RESULT

  • Shoemaker MB, Gidfar S, Pipilas DC, Tamboli RA, Savio Galimberti E, Williams DB, Clements RH, Darbar D. Prevalence and predictors of atrial fibrillation among patients undergoing bariatric surgery. Obes Surg. 2014 Apr;24(4):611-6. doi: 10.1007/s11695-013-1123-8.

    PMID: 24214203RESULT

  • Shoemaker MB, Bollmann A, Lubitz SA, Ueberham L, Saini H, Montgomery J, Edwards T, Yoneda Z, Sinner MF, Arya A, Sommer P, Delaney J, Goyal SK, Saavedra P, Kanagasundram A, Whalen SP, Roden DM, Hindricks G, Ellis CR, Ellinor PT, Darbar D, Husser D. Common genetic variants and response to atrial fibrillation ablation. Circ Arrhythm Electrophysiol. 2015 Apr;8(2):296-302. doi: 10.1161/CIRCEP.114.001909. Epub 2015 Feb 14.

    PMID: 25684755RESULT

  • Farrell M, Yoneda Z, Montgomery J, Crawford D, Wray LL, Xu M, Kolek MJ, Richardson T, Lugo R, Metawee M, Michaud G, Estrada JC, Saavedra P, Shen S, Kanagasundram A, Ellis CR, Crossley G, Roden D, Shoemaker MB. Non-pulmonary vein mediated atrial fibrillation: A novel sub-phenotype. PLoS One. 2017 Sep 7;12(9):e0184354. doi: 10.1371/journal.pone.0184354. eCollection 2017.

    PMID: 28880943DERIVED

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Moore B Shoemaker, MD, MSCI

    Vanderbilt University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
10 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Instructor

Study Record Dates

First Submitted

March 19, 2015

First Posted

March 31, 2015

Study Start

October 1, 2011

Primary Completion (Estimated)

October 1, 2028

Study Completion (Estimated)

October 1, 2028

Last Updated

April 27, 2026

Record last verified: 2026-04

Locations

US(1)